CD274 and non-small cell lung carcinoma: In CheckMate 017 and CheckMate 057, treatment with Nivolumab showed improved response rates and prognosis when PD-L1 was assessed as detectable (>1%) in non-squamous NSCLC but not in the squamous subtype [18,28].